Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRMDNASDAQ:HCMNASDAQ:MLTXNASDAQ:NAMS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRMDCorMedix$6.16-8.6%$10.31$3.61▼$13.85$401.52M1.53988,075 shs2.35 million shsHCMHUTCHMED$15.04-1.4%$14.78$12.84▼$21.92$2.62B0.77105,891 shs86,245 shsMLTXMoonLake Immunotherapeutics$39.07-2.0%$42.08$36.52▼$58.26$2.50B1.31339,175 shs685,088 shsNAMSNewAmsterdam Pharma$20.47-5.9%$21.60$15.19▼$27.29$2.39B-0.04534,360 shs1.52 million shsThe 10 Best Stocks to Own: Spring 2025Discover the 10 best stocks to own in Spring 2025, carefully selected for their growth potential amid market volatility. This exclusive report highlights top companies poised to thrive in uncertain economic conditions—download now to gain an investing edge.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRMDCorMedix-8.61%-42.80%-40.54%-23.95%+45.28%HCMHUTCHMED-1.38%-0.33%-8.63%+4.37%-10.48%MLTXMoonLake Immunotherapeutics-1.98%-3.72%-6.44%-27.85%-22.22%NAMSNewAmsterdam Pharma-5.93%-14.71%-2.52%-20.35%-13.45%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRMDCorMedix2.6042 of 5 stars4.61.00.00.03.10.00.6HCMHUTCHMED2.6871 of 5 stars3.03.00.00.03.60.01.9MLTXMoonLake Immunotherapeutics2.1296 of 5 stars3.51.00.00.03.52.50.0NAMSNewAmsterdam Pharma2.6056 of 5 stars3.51.00.00.03.44.20.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRMDCorMedix 3.13Buy$15.14145.83% UpsideHCMHUTCHMED 2.00Hold$19.0026.33% UpsideMLTXMoonLake Immunotherapeutics 3.00Buy$80.50106.04% UpsideNAMSNewAmsterdam Pharma 3.00Buy$43.33111.69% UpsideCurrent Analyst Ratings BreakdownLatest CRMD, NAMS, HCM, and MLTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/26/2025CRMDCorMedixRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$12.00 ➝ $12.003/26/2025CRMDCorMedixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $12.003/25/2025CRMDCorMedixD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/18/2025MLTXMoonLake ImmunotherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$67.003/7/2025CRMDCorMedixLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/7/2025CRMDCorMedixLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$18.003/5/2025CRMDCorMedixD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/3/2025NAMSNewAmsterdam PharmaUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$41.002/27/2025MLTXMoonLake ImmunotherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$82.00 ➝ $73.002/27/2025MLTXMoonLake ImmunotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$62.00 ➝ $66.002/27/2025MLTXMoonLake ImmunotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$100.00 ➝ $100.00(Data available from 4/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRMDCorMedix$43.47M9.24N/AN/A$1.28 per share4.81HCMHUTCHMED$630.20M4.16$0.61 per share24.51$4.27 per share3.52MLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$8.15 per shareN/ANAMSNewAmsterdam Pharma$45.56M49.34N/AN/A$3.50 per share5.85Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRMDCorMedix-$46.34M-$0.33N/A6.55N/AN/A-79.21%-64.68%5/8/2025 (Estimated)HCMHUTCHMED$100.78MN/A0.0010.30N/AN/AN/AN/A5/9/2025 (Estimated)MLTXMoonLake Immunotherapeutics-$36.01M-$1.89N/AN/AN/AN/A-15.54%-15.09%5/6/2025 (Estimated)NAMSNewAmsterdam Pharma-$176.94M-$2.60N/AN/AN/AN/AN/AN/A5/14/2025 (Estimated)Latest CRMD, NAMS, HCM, and MLTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/25/2025Q4 2024CRMDCorMedix$0.17$0.22+$0.05$0.22$27.46 million$30.00 million2/26/2025Q4 2024MLTXMoonLake Immunotherapeutics-$0.63-$0.72-$0.09-$0.72N/AN/A2/26/2025Q4 2024NAMSNewAmsterdam Pharma-$0.48-$0.95-$0.47-$0.95$3.30 million$12.77 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRMDCorMedixN/AN/AN/AN/AN/AHCMHUTCHMEDN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRMDCorMedixN/A3.963.60HCMHUTCHMED0.072.812.68MLTXMoonLake ImmunotherapeuticsN/A25.5125.51NAMSNewAmsterdam PharmaN/A10.6110.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRMDCorMedix34.18%HCMHUTCHMED8.82%MLTXMoonLake Immunotherapeutics93.85%NAMSNewAmsterdam Pharma89.89%Insider OwnershipCompanyInsider OwnershipCRMDCorMedix5.20%HCMHUTCHMED3.60%MLTXMoonLake Immunotherapeutics12.02%NAMSNewAmsterdam Pharma19.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRMDCorMedix3065.18 million57.52 millionOptionableHCMHUTCHMED1,988174.32 million168.04 millionNot OptionableMLTXMoonLake Immunotherapeutics264.01 million56.22 millionOptionableNAMSNewAmsterdam Pharma4109.82 million74.37 millionOptionableCRMD, NAMS, HCM, and MLTX HeadlinesRecent News About These CompaniesWilliam Blair Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)April 1 at 6:28 AM | markets.businessinsider.comPictet Asset Management Holding SA Buys 140,605 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)April 1 at 4:46 AM | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Sees Large Growth in Short InterestMarch 31 at 10:20 PM | marketbeat.comNewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare ConferenceMarch 31 at 8:12 AM | gurufocus.comNewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare ConferenceMarch 31 at 8:00 AM | globenewswire.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Acquired by Swiss National BankMarch 30 at 3:25 AM | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Director Buys $25,526.15 in StockMarch 29 at 7:20 PM | marketbeat.comJames N. Topper Buys 1,135 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) StockMarch 29 at 6:26 AM | insidertrades.comDirector Makes Bold Move with NewAmsterdam Pharma Stock Purchase!March 28, 2025 | tipranks.comNewAmsterdam Pharma deploys drone show in Chicago sky for heart disease awarenessMarch 28, 2025 | mmm-online.comDCF Advisers LLC Grows Position in NewAmsterdam Pharma (NASDAQ:NAMS)March 22, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Trading 3.4% Higher - What's Next?March 21, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Sold by US Bancorp DEMarch 18, 2025 | marketbeat.comNewAmsterdam Pharma Company (NAMS) Gets a Buy from Piper SandlerMarch 12, 2025 | markets.businessinsider.comNewAmsterdam Pharma (NASDAQ:NAMS) Receives Consensus Rating of "Buy" from BrokeragesMarch 11, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Director James N. Topper Purchases 4,005 SharesMarch 7, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Sees Large Volume Increase - Time to Buy?March 7, 2025 | marketbeat.comInsider Buying: NewAmsterdam Pharma (NASDAQ:NAMS) Director Buys 4,005 Shares of StockMarch 7, 2025 | insidertrades.comDirector’s Bold Move: Major Stock Purchase in NewAmsterdam Pharma!March 6, 2025 | tipranks.comNewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells $3,055,500.00 in StockMarch 6, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Up 3.9% - Should You Buy?March 5, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRMD, NAMS, HCM, and MLTX Company DescriptionsCorMedix NASDAQ:CRMD$6.16 -0.58 (-8.61%) Closing price 03/31/2025 04:00 PM EasternExtended Trading$6.08 -0.08 (-1.22%) As of 07:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.HUTCHMED NASDAQ:HCM$15.04 -0.21 (-1.38%) Closing price 03/31/2025 04:00 PM EasternExtended Trading$15.04 0.00 (-0.03%) As of 03/31/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.MoonLake Immunotherapeutics NASDAQ:MLTX$39.07 -0.79 (-1.98%) Closing price 03/31/2025 04:00 PM EasternExtended Trading$39.04 -0.03 (-0.08%) As of 03/31/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.NewAmsterdam Pharma NASDAQ:NAMS$20.47 -1.29 (-5.93%) Closing price 03/31/2025 04:00 PM EasternExtended Trading$20.45 -0.02 (-0.07%) As of 03/31/2025 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Buyable Stocks With Solid Bottoms Ready to Rebound Game-Changing News for Advanced Micro Devices Casey’s General Stores Insider Buys Shares of This Must-Own Stock U.S. Steel and Nippon Merger: Should Investors Bet on It? MarketBeat Week in Review – 03/24 - 03/28 JPMorgan: The 'NVIDIA of Banking' Poised for More Gains? Lululemon Pulls Back Into Classic Dip-Buying Opportunity Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
